ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., a leading innovator in women's health, has achieved a significant milestone with the European approval of its FemBloc® System, the first non-surgical permanent birth control solution. The system has received Conformité Européene $(CE)$ mark certification under the European Union Medical Device Regulation, marking the first regulatory approval of its kind globally. The FemBloc System, which includes a blended polymer component and a delivery system, can now be marketed across the European Economic Area. Femasys plans to roll out the product commercially in select European countries, beginning with Spain, while also pursuing further country approvals and continuing U.S. trials for FDA approval.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。